



A Web-App for Weight-Adjusted Red Cell Dosing: **Post-Development Implementation and Effectiveness**

S. Grey¹, K. Farrar, P. Kinsella², S. Roberts³, C. Patalappa³, S. Davies, Z. Ilyas¹, K. Littler Adamson⁴ Blood Transfusion¹, Haematology^{2,} Clinical Haematology^{3,} Blood Sciences⁴ Bolton NHS Foundation Trust, UK

Background

The empiric nature of red cell dosing can lead to over or under-transfusion when aiming to meet a post-transfusion haemoglobin target, especially if the patient's body weight is not accounted for. It is always important to clinically re-evaluate the patient after a single unit of red cells regardless of the total number administered. Repeat haemoglobin testing between units has a time and resource impact. This could be avoided if the volume required to meet the target haemoglobin value could be reliably predicted in the context of body weight. A web-app was developed, technically validated (Grey et al, 2016), CE marked as a class 1 medical device in 2016 by Bolton NHS Foundation Trust, and clinically implemented in 2017.

LINE DOGINI
10

💌 🔒 🍝 🔀 🔎 Live Search	P -
	Live Search

SERIOUS HAZARDS OF TRANSFUSION



Figure 1: web app page 1 (exclusion of non-appropriate patients)

Figure 2: web app page 2 (example data entry and calculated dose)

Method

Implementation strategy: executive-level organisational support, App hosted on intranet and or personal desk-top access, clinical and laboratory education and awareness, embedded in transfusion policy, re-design of red cell requesting process, monthly quality impact assessment with staff support and feedback.

Post-implementation data analysis: nine months' post implementation data were analysed to determine the level to which App was being used in clinical practice, clinical effectiveness was evaluated by audit of post-transfusion haemoglobin outcome, and impact on red cell usage.



Figure 5: projected 18% reduction in red cell usage

at 2017/18 financial year end

Discussion

The data suggest that the use of a web-app for weight –adjusted red cell dosing is effective in predicting the volume of red cells required to meet a target post-transfusion haemoglobin level in non-bleeding adult patients with normovolaemic anaemia. It has the advantage of limiting the need for repeat haemoglobin testing while continuing to clinically re-evaluate the patient after each unit, providing a more personalised approach to patient blood management. The data predicts a significant reduction in red cell usage and therefore a useful adjunct to other appropriate use of blood strategies. The app can be successfully implemented with high uptake in a committed organisation with a flexible and well supported approach.

A web-App for weight-adjusted red cell dosing: post-development implementation and clinical effectiveness. (2018). S. Grey, K. Farrar, P. Kinsella, S. Roberts, C. Patalappa, S. Davies, Z. Illyas, K. Littler Adamson. B J Haem, 181, (suppl. 1), p. 146

CONTACT DETAILS SHOT Office, Manchester, Blood Centre, Plymouth Grove, Manchester M13 9LL www.shotuk.org @shothv1 Tel: +44 (0) 161 423 4208 Enquiries: shot@nhsbt.nhs.uk Sharran Grey (Principal Clinical Scientist/Blood Transfusion Clinical Lead), Bolton NHS Foundation Trust (sharran.grey@boltonft.nhs.uk)